CV Science

Christine Durier Biostatistician / PhD Epidemiology

Course and current status

Since 1999 at INSERM SC10-US19 - Villejuif (in charge of the Biostatistics Team) 

Statistical Information Expert : Methodology and statistics of clinical trials in infectious diseases.   PhD Public health - Epidemiology (Paris-Est University)

Formerly at INRA - Biometry - Versailles: Statistical consulting and statistics of research projects (agro-food processes, food risk analysis, animal husbandry and nutrition).

Initial education: Agronomy Engineer (Montpellier SupAgro) specialized in Biometry at the Institut National Agronomique-Paris Grignon (Agro ParisTech).

Scientific summary

My main activity concerns the methodology and statistical analysis of academic clinical studies in immunology and vaccinology: immunotherapy in HIV infection and long-term tolerance of IL-2, vaccination of persons living with HIV (H1N1, yellow fever), preventive vaccines (HIV, malaria, COVID-19). 

For academic research on COVID-19, I contribute to the methodology for the COVIREIVAC platform and we are in charge of the statistics of the ANRS|MIE study "Vaccine effectiveness against severe COVID 19 in adults in France".

I also contribute in prevention of Hepatitis B mother-to-child transmission (Cambodia) and HIV reservoirs.

I have conducted research on inter-laboratory analysis of immune response methods used in vaccine and therapeutic trials (Elispot interferon-gamma, intracellular cytokines), meta-analysis of clinical tolerance data, and the study of the relationship between vaccine-induced seropositivity and psycho-social impact in volunteers participating in an HIV vaccine trial.

I am a member of Data and Safety Monitoring Boards (DSMB) for vaccine or therapeutic trials.

I am in scientific groups or committees for the ANRS-MIE,  and for INSERM, I have been a permanent member of the COSSEC Biothérapie (committee for organization and follow-up of clinical trials in cell and gene therapy) since 2010.

My skills concern the methodology of studies, through various study designs,  sample sizes, randomizations, statistical analyses, programs with SAS or R, presentations to scientific committees and independent DSMBs, publications (oral or poster communications, articles) and methodological expertise of research projects (HIV, hepatitis, vaccines, biotherapies).

and all statistical methods used in pre-clinical and clinical studies (survival data modelling, longitudinal data, fixed and random effects models, validation of analysis methods, inter-laboratory analyses) using SAS and R.